Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc's novel investigational candidate, pemvidutide, has demonstrated significant efficacy in reducing liver fat and improving key biomarkers, as evidenced by a MASLD trial showing up to 76% liver fat reduction and notable ALT improvements. The dual mechanism of action of pemvidutide, leveraging both GLP-1-driven weight loss and glucagon's impact on liver function, positions it favorably for treating both metabolic diseases and ALD, especially with a more favorable tolerability profile compared to existing incretin-based therapies. Additionally, the FDA's openness to non-invasive endpoints for regulatory approval could accelerate pemvidutide's path to market, enhancing its potential for widespread adoption and long-term success.

Bears say

The financial outlook for Altimmune Inc appears negative due to a significant net loss of $23.2 million in the fourth quarter of 2024 and ongoing concerns surrounding clinical development and competitive pressures within the biopharmaceutical sector. The market reception for approved obesity therapies, which includes pemvidutide, remains lukewarm, partly attributed to challenges such as low efficacy and compliance issues, despite the innovative attributes of pemvidutide itself. Additionally, the company faces multiple risks that could hinder its progress, including uncertainties related to reimbursement, commercialization, and external factors impacting clinical trial timelines.

Altimmune (ALT) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 13 analysts, Altimmune (ALT) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.